CLNN Clene: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The share price history of Clene Inc. (CLNN) allows for the tracking of performance metrics for the company, which specializes in creating gold catalysts to combat multiple sclerosis, where risks are mitigated by successful final trials. The current value of the metric is 0.00. The business relies on the development of nanoparticles against ALS, distributing projects across various testing stages. Innovations at the intersection of physics and biology accelerate neuron metabolism, preventing paralysis.
Analytical breakdowns for Clene Inc.
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
CLNN - Net Income|Expected Profit Clene Inc.|CLNN - Price to Earnings Ratio|Future Price to Earnings Clene|CLNN - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc.|CLNN - Operating profit before amortization|Earnings per share for the last twelve months Clene|CLNN - Earnings per share for the last 12 months|Quarterly EPS earnings growth clene.com|CLNN - Earnings per share growth rate in current year|Expected earnings per share growth for next year Clene Inc.
Fundamental company valuation:Clene Nanomedicine CLNN
This ratio relates the total enterprise value, including net debt, to operating profit before depreciation and amortization, determining the company's ability to service its obligations at the current cost of capital. By analyzing the change in the EV/EBITDA value over time, an investor can assess the financial stability of Clene Inc. (CLNN) amidst stringent regulatory costs for chemical waste disposal and the maintenance of specialized nanomedical laboratories.
Competitors of Clene Inc. (CLNN)
EV/EBITDA Multiple BIIB (Biogen Corp)|Neurocrine Corp (NBIX) - Company Value to EBITDA|RGC - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|AXSM (axsome.com) - Enterprise Value to Operating Income Before Depreciation|ACAD: EV/EBITDA Multiple|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to EBITDA Ratio VKTX|SUPN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPRX|Total Company Value to Operating Income Before Depreciation Ratio denalitherapeutics.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN: Enterprise Value to Operating Income Before Depreciation|Amylyx - EV/EBITDA Multiple|Trevi Corp (TRVI) - Enterprise Value to EBITDA Ratio|PRAX (Praxis Precision Medicines) - Enterprise Value to EBITDA Ratio|AVXL - Total Company Value to Operating Income Before Depreciation Ratio|CBLL (CeriBell) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Prothena Corporation PLC (PRTA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ANNX (Annexon Biosciences Inc.)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|NGNE: Enterprise Value to Operating Income Before Depreciation|ACIU - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|VYGR (Voyager Therapeutics Inc) - Enterprise Value to Operating Income Before Depreciation|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SCLX|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Company Value to EBITDA Alpha Cognition Corp ACOG|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|EV/EBITDA Multiple Inhibikase Therapeutics Inc (IKT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|Business Value to Operating Income Before Depreciation ASRT|COYA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Vistagen Therapeutics|OVID: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Acumen Pharmaceuticals Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ATHE|EV/EBITDA Multiple PEPG|JUNS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|ANVS: Enterprise Value to Operating Income Before Depreciation|Grace Tx - EV/EBITDA Multiple|Company Value to EBITDA Firefly Neuro|KLTO (anewmeds.com) - Enterprise Value to EBITDA Ratio|NeuroSense Therapeutics Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|MetaVia, Inc. (MTVA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|heliusmedical.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple PASG (Passage Bio)|NEUP - Enterprise Value to EBITDA Ratio|NERV: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Athira Pharma Inc ATHA|ADXN: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Alzamend Neuro|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PTIX|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|cortigent.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|BCLI: Enterprise Value to Operating Income Before Depreciation|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CHRO (chromocell.com) - Enterprise Value to Operating Income Before Depreciation|ELYM: EV/EBITDA Multiple|Company Value to EBITDA Intra-Cellular Therapies, Inc. (ITCI)|Enterprise Value to EBITDA Ratio LBPH|EV/EBITDA Multiple Marinus Pharma|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NKGen Biotech, Inc. (NKGN)|NRBO (neurobopharma.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Synaptogenix Inc. (SNPX) - Company Value to EBITDA|Trevena, Inc - EV/EBITDA Multiple|Vigil Neuroscience (VIGL) - Enterprise Value to EBITDA Ratio|Anew Medical, Inc. (WENA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CERE (cerevel.com) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
